The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Patients with low-risk myelodysplastic syndromes (LR-MDS) with bone marrow fibrosis (MF) display a cytokine pattern characterized by elevated interleukin 1β (IL-1β) and reduced interleukin 5 (IL-5), according to a presentation by Maria Stella Martino, MD, of the University of Florence in Italy and colleagues at the 2026 SOHO Annual Meeting.
In this video, Dr. Valeria Santini provides an overview of the SOHO 2026 MDS session. She covers novels agents and future research needs in the field.
Dr. Garcia-Manero introduces Neal Young, MD, of the National Heart, Lung, and Blood Institute (NHLBI) as the chosen plenary speaker, citing his foundational work in aplastic anemia.
A review of single-center studies showed that prophylactic use of tocilizumab in patients receiving step-up dosing of bispecific antibodies could reduce the severity of cytokine
A real-world study found that following relapse or progression after chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma (MM), bispecific antibodies significantly
A study assessing outcomes for the three FDA-approved BCMA-directed bispecific antibodies indicated for relapsed or refractory multiple myeloma (MM) found that linvoseltamab resulted in numerically
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
